Locations:
Search IconSearch
September 17, 2021/Cancer

Techniques and Lessons Learned: What to Know About Single-Port Extraperitoneal Radical Prostatectomy

Early experiences and outcomes on the brink of 200 cases

URL-Valleriano-1798462_12-20-19_Dr Kaouk in Surgery_MLC

Cleveland Clinic was the first U.S. medical center to begin using the single-port (SP) robot for urologic procedures in late 2018. Since then, experts at Glickman Urological & Kidney Institute continue to fine-tune their surgical technique.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Jihad Kaouk, MD, Director of the Center for Robotic and Image-Guided Surgery and the Zegarac-Pollock Endowed Chair in Laparoscopic and Robotic Surgery, elaborates on the benefits of performing the prostate cancer surgery extraperitoneally, noting, “By avoiding the sac in which the bowel is contained, the surgery is compartmentalized, limited to the area just around the prostate. The gas bubble in which the robotic arms work expands the peritoneum, pushing the bowel out of the way, allowing better visibility.”

In addition, the SP robotic technique avoids the steep Trendelenburg positioning, which improves recovery time and mitigates potential risks associated with such positioning, including optical nerve edema, congestion and respiratory problems during surgery. Patients undergoing the procedure with SP robotic prostatectomy lie flat. They experience a single incision, versus the five incisions required in a patient’s abdomen in previous robotic radical prostatectomy procedures.

These key differences in the SP robotic technique allow for easier extraperitoneal access, which helps avoid intra-abdominal adhesions. The technique also avoids assistant ports. Improved recovery aspects of the SP robotic procedure include decreased opioid use (70 percent of patients do not use opioids), an increase in same-day discharges with a median hospital stay of 4.8 hours, no drains and no reported ileus, with good functional and oncologic outcomes. Nearly 90 percent of patients were continent at six months.

Advertisement

The team shared their experience using the SP robot to perform extraperitoneal radical prostatectomy in 185 cases at the American Urological Association 2021 Annual Meeting.

Learn more in their virtual presentation:

SP Extraperitoneal Radical Prostatectomy: Technique and Lessons on the Brink of 200 Cases (Graphic)

Advertisement

Related Articles

Woman wearing pink scarf
January 17, 2025/Cancer/News & Insight
Exceptional Responders to Metastatic Breast Cancer Treatment Characterized

Findings may guide future research and personalized treatments

Tumor-Infiltrating Lymphocytes (TIL) therapy
January 6, 2025/Cancer/News & Insight
Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma

Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment

Woman with breast cancer
January 2, 2025/Cancer/News & Insight
Real-World Insights of KEYNOTE-522 Regimen Adoption for Treating Triple-Negative Breast Cancer

Real-world results reporting aims to make treatments safer and more effective

DNA strand
December 31, 2024/Cancer/News & Insight
New Data Further Support Breast Cancer Polygenic Risk Score

Ongoing clinical validation in diverse populations refine breast cancer risk substratification

Dr. Dermawan
December 24, 2024/Cancer/News & Insight
New Genomic Models for Leiomyosarcoma Treatment (Podcast)

Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification

Dr. Shahzad Raza
December 18, 2024/Cancer/News & Insight
Researchers Explore Prognostic Value of Transcriptomic Data in Multiple Myeloma

Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy

3D rendering of bispecific antibodies
December 17, 2024/Cancer/Blood Cancers
Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma

Ad